Bruker’s Molecular Phenomics Research Tools Enable New Insights into ‘Long COVID’ and Post-Acute Metabolic Abnormalities

Australian National Phenome Centre Integrates Quantitative NMR and MS Assay Platform for Risk Assessment and Longitudinal Monitoring of Post-Acute COVID-19 Syndrome (PACS)

Bruker’s Molecular Phenomics Research Tools Enable New Insights into ‘Long COVID’ and Post-Acute Metabolic Abnormalities

A clinical research collaboration on COVID-19 pheno-conversion and subsequent pheno-reversion has discovered transient and persistent systemic changes of the molecular signatures in patient blood samples three months after the acute COVID-19 disease phase. These biochemical abnormalities, identified by a quantitative, label-free assay platform integrating nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS), relate to ongoing ‘long COVID’ symptoms, which persist post-acute infection and can affect more than half of the recovered COVID patients – even six months after infection.

A series of seminal papers on the molecular phenome of acute disease and post-acute COVID syndrome in patient plasma has been announced ( and published (1-5) by the Australian National Phenome Centre (ANPC) at Murdoch University, in collaboration with other academic medical centers, and with Bruker Corporation (Nasdaq: BRKR) as a key technology partner.

The integrated, quantitative NMR and MS assay platform, which is for research use only, has revealed metabolic abnormalities, interactions of metabolic markers with cytokines, as well as interactions of lipoproteins with inflammation markers, caused by acute COVID-19. It enabled the creation of a multi-assay panel of pheno-conversion markers that change significantly during disease progression. This molecular phenomics panel can now also provide a measure of a patient’s partial recovery, or of emerging chronic PACS risks, e.g., for new-onset diabetes or for new-onset atherosclerosis, and for other persistent or reoccurring symptoms, including chronic fatigue, ‘brain fog’ and numerous other reported long COVID symptoms.

Post-acute follow up studies on non-hospitalized and mildly affected COVID-19 patients revealed that the majority of these patients is not back to normal health or normal biochemistry three months on and suffers from PACS, also referred to as ‘Long COVID’, characterized by persistent symptoms and health dysfunction after the acute infection. More than 57% of these patients show one or more symptoms up to six months following the acute phase, and many of them have metabolic abnormalities as revealed by the NMR and MS based pheno-reversion panel.

Professor Jeremy Nicholson, Pro Vice Chancellor for the Health Futures Institute at Murdoch University and Director of the ANPC explained: “Advanced NMR- and MS-screening of blood plasma provides complementary insights into the complex COVID-19 systemic pattern. There were multiple but variable biochemical abnormalities in the follow up patients with a variety of partial recovery phenotypes. We noted that most of the follow up COVID-19 patients had metabolic abnormalities irrespective of whether they were still symptomatic, but symptomatic patients were statistically more likely to have biochemical abnormalities.”

He continued: “This is an immensely dangerous disease that is not only costing lives today, but as we’re discovering now, may have serious health consequences for some patients long into the future, even in relatively mild original cases.”

The majority of patients at three months post-acute phase have a variety of blood metabolic abnormalities that differ between symptomatic and asymptomatic at six months. The researchers found that plasma lipoproteins in the blood of COVID-19 patients changed during infection and came closer to patterns typically found in patients with diabetes and atherosclerosis. Some abnormalities were reduced in the follow up patients and were reversible, whereas markers related to liver, energy metabolism and neuro-pathologies were often not completely reversed.

The latest research is consistent with earlier findings from the ANPC that showed COVID-19 is a systemic disease with multi-organ effects. The concept of pheno-conversion, as expressed in the lipoprotein and metabolic profile of blood plasma, establishes molecular phenotype biomarkers that can be analyzed for disease progression, severity and treatment. This underlines the importance of longitudinal studies on recovered patients for PACS effects and long-term health risks.

ANPC also devised a novel relaxation and diffusion edited NMR method that refined selectivity and led to the discovery of novel phospholipid signals from supramolecular clusters (3). “This is the first example of motional editing of complex blood plasma spectra to enhance the selectivity of a diagnostic procedure and opens the door to other NMR approaches to classification based on the dynamics of molecules, as well as on concentrations,” added Professor Nicholson.

Dr. Manfred Spraul, the CTO at Bruker BioSpin’s Applied, Industrial and Clinical Division, commented: “These findings underline the potential of our integrated NMR and MS assay platform for risk screening for PACS. Our research methods are robust and transferable for personalized molecular phenome signatures, providing a gateway to better understanding the long-term effects of COVID-19. These molecular phenotype insights are eventually expected to support better post-acute COVID-19 patient management for faster recovery, and a reduction in healthcare costs.”

The COVID-19 pheno-conversion and pheno-reversion signatures are detected by combined NMR and MS assays, providing complementary insights into potential biomarkers for cardiology, metabolism, diabetes, kidney disease, liver function, neurological effects, and inflammation.

Bruker has begun validation of this integrated NMR/MS clinical research assay set in Europe, with the goal of developing PACS personalized risk screening and longitudinal patient monitoring diagnostic methods.

Dr. Óscar Millet, Principal Investigator at CIC bioGUNE in Bilbao, Spain, commented: “As one of the key clinical research labs for precision medicine in Europe, we see huge potential for the PACS research enabled by high performance NMR and MS technology. We are an active member of the international COVID-19 research network, which is led by the ANPC. The harmonized research approach, which is based on standardized operating procedures developed by ANPC and Bruker, has allowed us to study PACS on Spanish patient cohorts and cross-validate our data with those of the ANPC at both the analytical and biological level.”

The studies were conducted using Avance™ IVDr NMR 600 MHz spectrometers integrated in the ANPC class II biosecurity laboratory, together with Bruker and CIC bioGUNE in-vitro diagnostics NMR research (IVDr) technology methods. The ANPC has also equipped its molecular phenomics lab with state-of-the-art mass spectrometers, including Bruker impact II and timsTOF™ Pro QTOF-MS, and a solariX™ MRMS system.

Bruker’s Molecular Phenomics Research Tools Enable New Insights into ‘Long COVID’ and Post-Acute Metabolic Abnormalities

Read the 120-page research report with TOC on “Cannabis-based Alcoholic Beverages Market Analysis Report by Product (Cannabis-infused beers, Cannabis-infused spirits, and Cannabis-infused wines) and by Geography (APAC, Europe, North America, South America and MEA,), and Segment Forecasts, 2020 – 2024.”

The market is driven by the increasing social acceptance of cannabis. In addition, the growing prominence of online retailing is also anticipated to drive the cannabis-based alcoholic beverages market growth during the forecast period.

The commonly held perception about cannabis being a mere intoxicant have changed across several nations. Over the past five years, the global legal cannabis-based edibles and cannabis-based alcoholic beverages market has been posting robust growth, tempting new vendors and large investors to leverage the potential offered by this industry. The growth of the cannabis market has significantly added to the income of several governments and boosted sales and revenue of major corporations. Therefore, with such advantages, it is expected that the global market will face a positive outlook in the forecast period. Furthermore, the growing popularity of online retailing has enabled vendors to improve their profit margins. The number of online transactions and the average amount of money spent online per transaction is increasing worldwide, which will further boost market growth over the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Cannabis-based Alcoholic Beverages Market Companies:

Anheuser-Busch InBev

The company’s key business segments include North America, Latin America West, Latin America North, Latin America South, EMEA, and Asia Pacific. The company offers cannabis mixed beers.

California Dreamin’

The company produces and distributes natural cannabis beers.


The company offers cannabis infused wines such as Cannavines Red Blend x Headband, Cannavines Chardonnay x Sour Diesel, and Rose X Grand Daddy Purple.

MJ Wines LLC

The company operates in key business segments including Energy Drinks, Wine, Cold Brew Coffee. The company offers terpene infused energy shot, hemp and cannabis wine formulations, and hemp cold brew coffee. The company offers hemp and cannabis-based wine formulations.

Heineken NV

The company operates in key business segments including Europe, Americas, Africa, Middle East and Eastern Europe, Asia Pacific, and Heineken N.V. Head Office & Others. The company through its brand, Lagunitas Brewing Co. offers cannabis-based beer.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Cannabis-based Alcoholic Beverages Product Outlook (Revenue, USD Million, 2020 – 2024)

  • Cannabis-infused beers
  • Cannabis-infused spirits
  • Cannabis-infused wines

Cannabis-based Alcoholic Beverages Regional Outlook (Revenue, USD Million, 2020 – 2024)

  • APAC
  • Europe
  • North America
  • South America
  • MEA

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Consumer Staples are:

Global Alcoholic Beverages Market 2019-2023 – Global alcoholic beverages by product (beer, spirits, and wine) and geography (APAC, Europe, MEA, North America, and South America).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Bruker’s Molecular Phenomics Research Tools Enable New Insights into ‘Long COVID’ and Post-Acute Metabolic Abnormalities

The Montreal Heart Institute (MHI) today announced that the COLCORONA clinical trial will continue to recruit non-hospitalized adult patients with COVID-19 as recommended by the independent data monitoring committee (DMC), following a second interim analysis.

“With the dramatic rise in COVID-19 cases across the world, it is becoming even more critical that we continue to investigate treatments that can not only help those hospitalized with severe disease, but also those with less severe symptoms who are able to remain at home,” said Dr. Jean-Claude Tardif, Director of the Research Center at MHI, Professor of Medicine at the University of Montreal, and COLCORONA principal investigator. “We aim at completing patient recruitment in this large study within the next month and hope that colchicine will reduce the risk of COVID-19 complications.”

COLCORONA is a contact-free, at-home, randomized, double-blind, placebo-controlled study run out of Canada, the United States, Europe, South America, and South Africa. It aims to determine if colchicine can reduce the risk of serious complications linked to COVID-19. This is one of the few current large-scale studies of COVID-19 in which non-hospitalized patients can participate. Participants and physicians interested in COLCORONA can call the hotline at 1-877-536-6837.

COLCORONA is coordinated by the Montreal Health Innovations Coordinating Center (MHICC) and funded by the Government of Quebec, the Bill & Melinda Gates Foundation and the National Heart, Lung, and Blood Institute (NHLBI) of the United States National Institutes of Health (NIH). CGI, Dacima and Pharmascience are also collaborators of COLCORONA.

The Montreal Heart Institute and its partners worldwide would like to thank all the investigators and the thousands of participants for their continued participation in the COLCORONA study.

Scroll to top